Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19
Jonathan H. Shrimp(National Institutes of Health), Matthew D. Hall(National Institutes of Health), Stephen C. Kales(National Institutes of Health), Wei Zheng(Liaoning Cancer Hospital & Institute), John Janiszewski(National Institutes of Health), Zina Itkin(National Institutes of Health), Carleen Klumpp‐Thomas(National Institutes of Health), Rick Schneider(National Institutes of Health), Sam Michael(National Institutes of Health), Anton Simeonov(National Institutes of Health), Philip E.J. Sanderson, Min Shen(Kaili University), Miao Xu(National Institutes of Health), Hui Guo(First Affiliated Hospital of Xi'an Jiaotong University), Catherine Z. Chen(National Institutes of Health), Paul Shinn(National Institutes of Health), Kelli M. Wilson(National Institutes of Health)
Cited by 8
Related Papers
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium
|Cell stem cell|2020|460
Unexplored therapeutic opportunities in the human genome
|Nature Reviews Drug Discovery|2018|391
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
|Cancer Cell|2015|348
Erratum: Unexplored therapeutic opportunities in the human genome
|Nature Reviews Drug Discovery|2018|327
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
|Science Translational Medicine|2019|259